Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Rhea-AI Summary

Citius Oncology (Nasdaq: CTOR) reported first reported revenue of $3.9 million from the December 2025 commercial launch of LYMPHIR (denileukin diftitox-cxdl) and provided fiscal Q1 2026 results for the quarter ended December 31, 2025. The company is now a commercial-stage oncology firm with an FDA-approved IL-2 receptor-directed therapy for relapsed or refractory Stage I–III CTCL.

Other Q1 highlights include $7.3 million cash on hand, a December registered offering that raised net proceeds of $15.1 million, R&D of $1.0 million, G&A of $2.9 million, and a net loss of $5.5 million ($(0.06) per share).

Positive

• First revenue of $3.9M from LYMPHIR launch in December 2025
• FDA-approved commercial product for relapsed/refractory Stage I–III CTCL
• Registered offering generated $15.1M net proceeds in December 2025
• Nationwide distribution established to enable immediate product availability

Negative

• Net loss of $5.5M in fiscal Q1 2026
• Stock-based compensation of $4.0M in the quarter, materially above prior-year
• Cash balance of $7.3M as of December 31, 2025 may limit runway without further funding

Key Figures

Quarterly revenue: $3.9 million Cash and equivalents: $7.3 million Registered offering proceeds: $15.1 million +5 more

8 metrics

Quarterly revenue $3.9 million Quarter ended December 31, 2025; initial LYMPHIR sales

Cash and equivalents $7.3 million As of December 31, 2025

Registered offering proceeds $15.1 million Net proceeds from December 2025 registered offering

R&D expense $1.0 million Q1 2026 vs $1.3 million prior-year period

G&A expense $2.9 million Q1 2026 vs $3.3 million prior-year period

Stock-based compensation $4.0 million Q1 2026 vs $1.8 million prior-year period

Net loss $5.5 million Q1 2026 vs $6.7 million prior-year period

EPS $(0.06) per share Q1 2026 vs $(0.09) prior-year period

Market Reality Check

Price: $1.18 Vol: Volume 403,626 is 2.09x t...

high vol

$1.18 Last Close

Volume Volume 403,626 is 2.09x the 20-day average of 193,566, indicating elevated interest ahead of this report. high

Technical Price at $1.18 is trading below the 200-day MA of $1.61, reflecting a longer-term downtrend despite recent strength.

Peers on Argus

CTOR was up 4.42% while close peers showed mixed moves: IRWD up 3.83%, SXTC up 3...

1 Up 1 Down

CTOR was up 4.42% while close peers showed mixed moves: IRWD up 3.83%, SXTC up 3.54%, BIOA and DERM down 3–4%. Momentum scanner saw one peer up and one down, supporting a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	EU access agreement	Positive	+0.0%	Expanded LYMPHIR access in Europe via Uniphar managed access programs.
Dec 23	FY25 results	Neutral	+1.6%	Reported FY25 figures and financing activity following LYMPHIR launch preparations.
Dec 23	Parent FY25 update	Neutral	+1.6%	Parent company business update highlighting LYMPHIR launch and access milestones.
Dec 10	Offering closing	Negative	-2.6%	Closed $18M registered direct and private placement supporting LYMPHIR launch.
Dec 09	Offering announcement	Negative	+6.4%	Announced $18M concurrent offering; stock initially reacted positively despite dilution.

Pattern Detected

Recent financings and commercialization milestones have generally seen modestly positive or aligned price reactions, with one notable divergence on an offering announcement.

Recent Company History

Over the last few months, CTOR has moved from financing its launch to executing on commercialization. December 2025 offerings (news IDs 945743, 946572) funded LYMPHIR’s rollout, with mixed immediate reactions. Fiscal 2025 results and a broader Citius Pharma update (news IDs 951225, 951226) coincided with small gains. The February 11, 2026 European distribution deal (news ID 1011461) saw no price change, framing today’s first revenue report as the next step in the same commercialization arc.

Market Pulse Summary

This announcement marks CTOR’s transition to a commercial oncology company, with first-quarter LYMPH...

Analysis

This announcement marks CTOR’s transition to a commercial oncology company, with first-quarter LYMPHIR revenue of $3.9 million and cash of $7.3 million as of December 31, 2025. Operating metrics show lower R&D and G&A and an improved net loss of $5.5 million, offset by higher stock-based compensation of $4.0 million. Investors may watch future quarters for revenue trajectory, cash management, and progress in combination studies and international access programs.

Key Terms

registered offering, ai-enabled commercial platform, immunotherapy, phase i, +3 more

7 terms

registered offering financial

"Completed a registered offering in December 2025, generating net proceeds..."

A registered offering is the public sale of a company’s stocks or bonds that has been filed with and approved by the securities regulator, accompanied by an official disclosure document (prospectus). It matters to investors because the required disclosures provide a clear, regulator‑approved “brochure” about the deal — helping buyers assess risk, potential dilution of existing shares, and how the company plans to use the proceeds, similar to reading a menu before ordering.

ai-enabled commercial platform technical

"supported by an advanced AI-enabled commercial platform designed to drive efficient..."

An ai-enabled commercial platform is a software product businesses use to deliver or improve commercial activities that embeds artificial intelligence to automate, analyze, or optimize tasks such as customer interactions, sales, supply chains, or personalization. Investors care because AI can allow the platform to serve more customers at lower cost and create a competitive edge—like replacing repetitive manual work with a smart assistant—so revenue and profit potential hinge on data quality, scalability and ongoing operating costs.

immunotherapy medical

"with an FDA-approved IL-2 receptor-directed immunotherapy for adult patients..."

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

phase i medical

"investigator-initiated Phase I combination studies evaluating LYMPHIR..."

A Phase I clinical trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety and finding an appropriate dose by studying a small group of volunteers or patients. Investors watch Phase I results because they reveal early signs of safety, tolerability and how the body handles the treatment—information that helps gauge development risk and the likelihood and timing of later, larger trials that drive a drug’s value, much like a test drive reveals whether a prototype is worth further investment.

car-t therapy medical

"as part of lymphodepletion regimens prior to CAR-T therapy..."

CAR-T therapy is a type of medical treatment that uses a patient's own immune cells, specially modified to better recognize and attack cancer cells. For investors, it represents a significant advancement in cancer care, with the potential to transform treatment options and generate substantial demand, making companies involved in its development and production potentially valuable in the healthcare industry.

named patient programs regulatory

"Named Patient Programs (NPPs) in key European and Middle Eastern markets..."

Named patient programs are arrangements that allow patients to access experimental or unapproved medicines outside of regular clinical trials, often through special approvals. They matter to investors because they can signal a company's efforts to bring new treatments to market and may impact perceptions of future sales potential or regulatory progress. These programs can also influence a company's reputation and relationships within the healthcare industry.

stock-based compensation financial

"Stock-based compensation expense totaled $4.0 million, primarily related to equity grants..."

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

AI-generated analysis. Not financial advice.

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update.

"The first quarter of fiscal 2026 marked a pivotal inflection point for Citius Oncology with the successful U.S. commercial launch of LYMPHIR and the Company's first reported revenue," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma. "This transition from a development-stage organization to a commercial oncology company reflects years of deliberate preparation and coordination across our clinical, manufacturing, distribution, and commercial infrastructure."

"With initial distributor sales complete nationwide, we are now focused on accelerating physician adoption and expanding patient access. Since the start of calendar 2026, physicians have begun to initiate patients on LYMPHIR, and our formulary review efforts are progressing as planned. We are preparing to expand our field presence to support a highly concentrated prescriber base in this rare cancer setting, supported by an advanced AI-enabled commercial platform designed to drive efficient market penetration," added Mazur.

"As LYMPHIR is now broadly available, we remain focused on execution, capital management, and evaluating strategic opportunities that we believe can meaningfully enhance long-term shareholder value," concluded Mazur.

Business Highlights and Subsequent Developments

• Initiated U.S. commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) in December 2025, establishing Citius Oncology as a commercial-stage oncology company with an FDA-approved IL-2 receptor-directed immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;
• Established nationwide specialty distribution infrastructure, completing initial distributor sales to ensure immediate product availability across U.S. treatment centers and support rapid physician adoption;
• Initiated treatment of CTCL patients at leading U.S. cancer centers;
• Deployed an AI-enabled commercial platform to drive targeted physician engagement, optimize field execution, and efficiently penetrate a highly concentrated prescriber base; and,
• Advanced international access strategy outside the U.S. through regional distribution partners and Named Patient Programs (NPPs) in key European and Middle Eastern markets, enabling patient access where permitted by local law without constituting commercial approval;
• Continued to expand long-term value optionality through investigator-initiated Phase I combination studies evaluating LYMPHIR:
• in combination with pembrolizumab in patients with recurrent solid tumors; and,
• as part of lymphodepletion regimens prior to CAR-T therapy, supporting potential future label expansion opportunities.

First Quarter 2026 Financial Highlights

• Cash and cash equivalents totaled $7.3 million as of December 31, 2025;
• Completed a registered offering in December 2025, generating net proceeds of approximately $15.1 million;
• Revenue of $3.9 million during the quarter ended December 31, 2025 reflects sales related to the launch of LYMPHIR;
• Research and development expenses were $1.0 million, compared to $1.3 million in the prior-year period, reflecting reduced clinical development activity;
• General and administrative expenses were $2.9 million, compared to $3.3 million in the prior-year period;
• Stock-based compensation expense totaled $4.0 million, primarily related to equity grants issued in September 2025, compared to $1.8 million in the prior-year period; and,
• Net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 75% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to maintain Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

-- Financial Tables Follow –

 

CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
		December 31, 2025				September 30, 2025
Current Assets:
Cash and cash equivalents		$	7,295,451			$	3,924,908
Accounts receivable, net of allowances			4,049,111				—
Inventory			22,639,342				22,286,693
Prepaid expenses			3,162,940				1,331,280
Total Current Assets			37,146,844				27,542,881
Other Assets:
In-process research and development, net of accumulated amortization			72,826,562				73,400,000
Total Other Assets			72,826,562				73,400,000
Total Assets		$	109,973,406			$	100,942,881
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$	10,446,900			$	13,234,684
License payable			18,250,000				22,650,000
Accrued expenses			4,518,916				4,093,124
Due to related party			11,494,578				9,513,771
Total Current Liabilities			44,710,394				49,491,579
Deferred tax liability			3,049,200				2,784,960
Note payable to related party			3,800,111				3,800,111
Total Liabilities			51,559,705				56,076,650
Stockholders' Equity:
Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued      and outstanding			—				—
Common stock - $0.0001 par value; 400,000,000 shares authorized at December 31,      2025 and September 30, 2025; 84,797,846 and 83,513,442 shares issued and      outstanding at December 31, 2025 and September 30, 2025, respectively			8,480				8,351
Additional paid-in capital			127,979,246				108,897,836
Accumulated deficit			(69,574,025)				(64,039,956)
Total Stockholders' Equity			58,413,701				44,866,231
Total Liabilities and Stockholders' Equity		$	109,973,406			$	100,942,881

 

CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 (Unaudited)
		Three Months Ended
		December 31,				December 31,
		2025				2024
Revenue		$	3,944,111			$	—
Cost of revenues			(789,208)				—
Gross Profit			3,154,903				—
Operating Expenses
Research and development			1,018,352				1,264,508
Amortization of in-process research and development			573,438				—
General and administrative			2,859,339				3,321,979
Stock-based compensation – general and administrative			3,956,050				1,808,478
Total Operating Expenses			8,407,179				6,394,965
Operating Loss			(5,252,276)				(6,394,965)
Other Income (Expense)
Interest income			28,288				—
Interest expense			(45,841)				—
Total Other Income (Expense), Net			(17,553)				—
Loss before Income Taxes			(5,269,829)				(6,394,965)
Income tax expense			264,240				264,240
Net Loss		$	(5,534,069)			$	(6,659,205)
Net Loss Per Share - Basic and Diluted		$	(0.06)			$	(0.09)
Weighted Average Common Shares Outstanding
Basic and diluted (includes pre-funded warrants from the December 2025 offering)			87,462,385				71,552,402

 

CITIUS ONCOLOGY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 (Unaudited)
		2025				2024
Cash Flows From Operating Activities:
Net loss		$	(5,534,069)			$	(6,659,205)
Adjustments to reconcile net loss to net cash provided by operating activities:
Stock-based compensation expense			3,956,050				1,808,478
Amortization of in-process research and development			573,438				-
Deferred income tax expense			264,240				264,240
Changes in operating assets and liabilities:
Accounts receivable, net of allowances			(4,049,111)				-
Inventory			(352,649)				(6,112,603)
Prepaid expenses			(1,831,660)				-
Accounts payable			(2,787,784)				2,162,955
Accrued expenses			425,792				6,228,612
Due to related party			1,980,807				2,307,523
Net Cash (Used In) Provided By Operating Activities			(7,354,946)				-
Cash Flows From Investing Activities
License payments			(4,400,000)				-
Net Cash Used In Investing Activities			(4,400,000)				-
Cash Flows From Financing Activities
Net proceeds from issuance of common stock			15,125,489				-
Net Cash Provided by Financing Activities			15,125,489				-
Net Change in Cash and Cash Equivalents			3,370,543				-
Cash and Cash Equivalents – Beginning of Period			3,924,908				112
Cash and Cash Equivalents – End of Period		$	7,295,451			$	112
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:
Interest Paid		$	14,460			$	-

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-announces-first-reported-revenue-following-successful-launch-of-lymphir-302687114.html

SOURCE Citius Oncology, Inc.

FAQ

How much revenue did Citius Oncology (CTOR) report from the LYMPHIR launch in December 2025?

Citius Oncology reported $3.9 million in revenue from initial LYMPHIR sales. According to the company, these sales reflect initial distributor shipments completed nationwide during December 2025 supporting immediate product availability.

What were Citius Oncology's (CTOR) fiscal Q1 2026 results for net loss and EPS?

Citius Oncology posted a $5.5 million net loss, or $(0.06) per share for fiscal Q1 2026. According to the company, this compares to a prior-year net loss of $6.7 million, or $(0.09) per share.

How much cash did Citius Oncology (CTOR) have after the December 2025 registered offering?

Citius Oncology reported $7.3 million in cash and equivalents as of December 31, 2025. According to the company, the balance follows a December registered offering that generated approximately $15.1 million in net proceeds.

What is LYMPHIR approved for and when did Citius Oncology (CTOR) launch it commercially?

LYMPHIR is FDA-approved for adult patients with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy. According to the company, the U.S. commercial launch occurred in December 2025.

How is Citius Oncology (CTOR) supporting uptake of LYMPHIR after the December 2025 launch?

Citius Oncology is focusing on physician adoption with an AI-enabled commercial platform and expanded field presence. According to the company, distributor sales are complete nationwide and physicians began initiating patients in early 2026.

Does Citius Oncology (CTOR) have international access plans for LYMPHIR following the U.S. launch?

Citius Oncology is advancing an international access strategy via regional distributors and Named Patient Programs in Europe and the Middle East. According to the company, these NPPs enable patient access where permitted without constituting commercial approval.